NCT01521793View on ClinicalTrials.gov

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

June 30, 2014

Conditions
LCA (Leber Congenital Amaurosis)RP (Retinitis Pigmentosa)
Interventions
DRUG

QLT091001

oral QLT091001 administered once daily for 7 days

Trial Locations (6)

21287

Wilmer Eye Institute (Johns Hopkins University), Baltimore

60608

The Chicago Lighthouse (University of Illinois at Chicago, Pangere Center for Inherited Retinal Disease), Chicago

Unknown

Montreal Children's Hospital, McGill University Health Centre, Montreal

Institute for Ophthalmic Research, University of Tubingen, Tübingen

The Rotterdam Eye Hospital, Rotterdam

EC1 V2PD

Moorefield Eye Hospital, London

All Listed Sponsors
lead

QLT Inc.

INDUSTRY

NCT01521793 - Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01) | Biotech Hunter | Biotech Hunter